The largest database of trusted experimental protocols

Ertapenem

Manufactured by MSD
Sourced in France

Ertapenem is a broad-spectrum antibiotic used in the treatment of various bacterial infections. It belongs to the class of carbapenem antibiotics and functions by inhibiting the synthesis of the bacterial cell wall, thereby disrupting the structural integrity of the pathogen. Ertapenem demonstrates activity against a wide range of Gram-positive and Gram-negative bacteria, including certain drug-resistant strains.

Automatically generated - may contain errors

5 protocols using ertapenem

1

Porcine Bacteremia Model with ESBL E. coli

Check if the same lab product or an alternative is used in the 5 most similar protocols
To induce a porcine bacteremia model, extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (5.0 * 10^9 CFU, Strain: BAA-196, ATCC, Manassas, VA) was diluted in 1000 mL of normal saline and intravenously administered over the course of an hour to subjects (Fig. 1). After complete infusion of bacteria, the pigs were assigned to two groups of antibiotics, ceftriaxone (2 g, Cerixone, Chong Kun Dang, Seoul, Rep. of Korea) or ertapenem (2 g, Invanz, MSD, Whitehouse Station, NJ). One hour after the completion of bacterial infusion and acquisition of blood samples, including culture, antibiotics were administered to the subject as allocated.
The animals were monitored up to 7 h after completion of bacterial infusion, and the primary goal was to maintain over 65 mmHg of MAP. Balanced crystalloid solution (Plasma Solution A, HK inno. N, Seoul, Republic of Korea) was challenged when MAP was less than 65 mmHg, and vasopressors consisting of norepinephrine, vasopressin, and epinephrine were sequentially initiated when the cumulative fluid exceeded 30 mL/kg or target MAP was not achieved with bolus fluid.
+ Open protocol
+ Expand
2

Quantification of Antimicrobial Agents in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Amoxicillin, ciprofloxacin, ofloxacin, clindamycin, cefotaxime, and piperacillin were purchased from Sigma (St. Gallen, Louis, MO, USA). Monohydrate cefepime dichlorhydrate was supplied from Gerda (Paris, France). Trihydrate meropenem and sodium cefoxitin were supplied from Panpharma (Fougères, France). Pentahydrate ceftazidime and sodium cefazolin were supplied from Mylan (Saint Priest, France). Ertapenem was supplied from MSD (Puteaux, France). Daptomycin was supplied from Medac SAS (Lyon, France). Aztreonam was supplied from Sanofi Aventis (Gentilly, France). Linezolid was supplied from Fresenius Kabi (Sevres, France). Internal standards (Amoxicillin-D4, cefazolin-13C215N, meropenem-D6, ofloxacin-D8, ciprofloxacin-D8, piperacillin-D5, cefotaxime-D3, and Linezolid-D3) were purchased from TRC (Toronto, ON, Canada). Acetonitrile, methanol, formic acid, and water, all LC-MS hypergrade for mobile phase, were obtained from Biosolve (Dieuze, France). Plasma was purchased from the French Blood Bank (“Etablissement Français du Sang”, EFS, Reims, France).
+ Open protocol
+ Expand
3

Antimicrobial Susceptibility of Bacterial Isolates

Check if the same lab product or an alternative is used in the 5 most similar protocols
The antimicrobial susceptibility of the two investigated isolates were tested according to the Clinical Laboratory Standard Institute guidelines, CLSI (M100-S32, 2022) recommendations using Escherichiacoli ATCC 25922 as quality control strain [14 ]. The investigated isolates were tested against the following antimicrobial agents, viz., ampicillin (30 µg), cefepime (30 µg), ceftriaxone (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), aztreonam (30 µg), ertapenem (10 µg), imipenem (10 µg), meropenem (10 µg), amikacin (10 µg), gentamicin (10 µg) and ciprofloxacin (5 µg) (HiMedia, India) via Kirby-Bauer disc diffusion method. The minimal inhibitory concentrations (MICs) of ertapenem (MSD, France), imipenem (Merck, France) and meropenem (AstraZeneca, UK) were determined through agar dilution method (concentration range : 1–64 µg/ml).
+ Open protocol
+ Expand
4

Antibiotic Susceptibility Testing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All antibiotic susceptibilities were performed according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [39 ]. The minimum inhibitory concentrations (MICs) of imipenem (Apollo Scientific, Manchester, UK), meropenem (Sigma-Aldrich, Steinheim, Germany), ertapenem (MSD, Kenilworth, NJ, USA), ceftriaxone (Sigma-Aldrich, Steinheim, Germany), and amikacin (Sigma-Aldrich, Germany) were determined by using broth microdilution method with cation-adjust Mueller–Hinton broth (CAMHB) (Becton Dickenson BBL, Sparks, MD, USA). Fosfomycin (Wako Pure Chemical Industries, Osaka, Japan) susceptibility was performed by agar dilution method using Mueller–Hinton agar supplemented with 25 mg/L of glucose-6-phosphate (G6P) (Sigma-Aldrich, Steinheim, Germany). Azithromycin (Sigma-Aldrich, Steinheim, Germany) susceptibility test was determined by broth microdilution method. E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as reference control strains for susceptibility testing. The antibiotic susceptibility was interpreted according to EUCAST guidelines (Supplementary Materials Table S2).
+ Open protocol
+ Expand
5

Cloning and expression of bacterial genes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Kanamycin was purchased from MP Biomedicals, France. Ampicillin from SA Bristol-Myers Squibb Belgium,N.V. Imipenem and Ertapenem from MSD , Belgium. Meropenem from Astro Zeneca Belgium. Doripenem and Biapenem were purchased from Sigma Aldrich, Belgium. E.coli DH5α (Life Technologies, Belgium) and E. coli Rosetta (DE3) (Novagen Inc., Madison, Wis.) were used as recipient on the cloning gene step and enzyme expression. The gene was cloned initially into pJET1.2 vector (Thermo Fischer Scientific, Belgium) and after subcloned into pET-26b (Novagen Inc., Madison, Wis).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!